Medicine
Gavreto 100 mg capsule
Gavreto 100 mg capsule is a prescription medicine containing Pralsetinib for oral use, marketed by Rigel Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions are permitted from 15°C to…
Key facts
- Active ingredient (INN)
- Pralsetinib
- Brand
- Gavreto
- Strength
- 100 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 120 capsules, 60 capsules, 90 capsules
- Marketing authorisation holder
- Rigel Pharmaceuticals
- Manufacturer
- Rigel Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions are permitted from 15°C to 30°C (59°F to 86°F). Protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01EX23 Pralsetinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 June 2024
- Identifiers
- RxCUI 2394941, 2394947DailyMed set ID 16edd46e-28b8-f06d-e063-6394a90ae31bNDC 71332-006Application NDA213721
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 120 capsule in 1 bottle | 71332-006-12 | Rigel Pharmaceuticals | 24 June 2024 |
| 60 capsule in 1 bottle | 71332-006-60 | Rigel Pharmaceuticals | 24 June 2024 |
| 90 capsule in 1 bottle | 71332-006-90 | Rigel Pharmaceuticals | 24 June 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Pralsetinib is a kinase inhibitor indicated for treatment of adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC), among other approved uses. MedsAcross supplies Pralsetinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PralsetinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Gavreto prescribing information (Rigel Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Gavreto 100 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.